Carol DePriest

Hoag Memorial Hospital Presbyterian — United States

Immunology and Microbiology · Life Sciences

19h-index944citations56works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(37), Cancer Immunotherapy and Biomarkers(31), CAR-T cell therapy research(21), Cancer Research and Treatments(12), Renal cell carcinoma treatment(8)

Publications56 total

Patient-Specific Dendritic Cell Vaccines with Autologous Tumor Antigens in 72 Patients with Metastatic Melanoma
Melanoma Management·2019· 17 citedOpen Access
Survival by stage and tumor measurability in metastatic melanoma patients treated with autologous dendritic cell tumor cell vaccines.
Journal of Clinical Oncology·2019
Dendritic Cell Vaccines Presenting Autologous Tumor Antigens from Self-renewing Cancer Cells in Metastatic Renal Cell Carcinoma
Journal of Exploratory Research in Pharmacology·2018· 8 citedOpen Access
Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
Journal for ImmunoTherapy of Cancer·2018· 71 citedOpen Access
Abstract CT105: Randomized trial of dendritic vs tumor cell patient-specific vaccines: 5-year analysis
Cancer Research·2016· 1 cited
5-year follow up for 72 metastatic melanoma patients treated with eltrapuldencel-T (CLBS20) vaccine.
Journal of Clinical Oncology·2016
Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines
Journal for ImmunoTherapy of Cancer·2015Open Access
Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment
Cancer Biotherapy and Radiopharmaceuticals·2015· 22 citedOpen Access
Abstract 197: 5-year survival for patients with metastatic melanoma who had no evidence of disease at time of treatment with patient specific tumor stem cell vaccines
Cancer Research·2014· 3 cited
Long-term survival for patients with detectable metastatic melanoma at time of treatment with patient-specific tumor stem cell vaccines.
Journal of Clinical Oncology·2014· 2 cited
High-Dose IL2 in Metastatic Melanoma: Better Survival in Patients Immunized with Antigens from Autologous Tumor Cell Lines
Cancer Biotherapy and Radiopharmaceuticals·2013· 16 citedOpen Access
High-dose IL-2 in metastatic melanoma: better survival in patients who also received patient-specific autologous tumor cell vaccine
Journal for ImmunoTherapy of Cancer·2013Open Access
Cancer Stem Cell Antigens from Autologous Tumor Cell Lines in Patient-Specific Active Immunotherapy for Metastatic Cancer
2012· 1 cited
Tumor Stem Cell Antigens as Consolidative Active Specific Immunotherapy
Journal of Immunotherapy·2012· 74 cited
Patient-specific immunotherapy utilizing putative tumor stem cells in patients with metastatic melanoma: A pooled analysis comparing tumor cell and dendritic cell vaccines in two phase II trials and a randomized phase II trial.
Journal of Clinical Oncology·2012
Abstract 3703: Randomized trial of autologous dendritic cell vs tumor cell vaccines in patients with metastatic melanoma
Cancer Research·2012· 1 cited
Features Associated with Survival in Metastatic Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines
Cancer Biotherapy and Radiopharmaceuticals·2011· 20 cited
Durable Complete Response of Refractory, Progressing Metastatic Melanoma After Treatment with a Patient-Specific Vaccine
Cancer Biotherapy and Radiopharmaceuticals·2010· 23 cited
Phase II Trial of Dendritic Cells Loaded with Antigens from Self-Renewing, Proliferating Autologous Tumor Cells as Patient-Specific Antitumor Vaccines in Patients with Metastatic Melanoma: Final Report
Cancer Biotherapy and Radiopharmaceuticals·2009· 67 cited
RE: Response to Letter to the Editor by Kay Et Al.
Cancer Biotherapy and Radiopharmaceuticals·2007
page 1 of 3Next →

Frequent Co-authors

Robert O. Dillman(46), Cristina de Leon(18), Curtis K. Church(15), Linda D. Beutel(14), Neil M. Barth(14), Senthamil R. Selvan(13), Patric M. Schiltz(12), Shankar K. Nayak(12), Andrew N. Cornforth(10), Michael C. Wiemann(10), Gamini S. Soori(10), Edward F. McClay(9), Khosrow Mahdavi(7), Cheryl Peterson(6), Thomas Amatruda(5), Kanoe Allen(5), Martin J. Bury(5), Audrey A. OʼConnor(4), D. F. Tai(4), James J. Stark(4)